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Background: Combined heart and kidney transplantation has been documented,
although data regarding immunosuppression, rejection episodes, and graft or patient
survival have not been detailed. We evaluated our experience and more than 10-year
outcome with patients selected for combined heart and kidney transplantation.
Methods: Eight patients aged 29 to 59 years were selected for combined heart and
kidney transplantation. The indications were end-stage heart disease and underlying
renal pathology, or secondary renal insufficiency, or renal failure. Six patients were
dialysis dependent before transplantation. There were 7 simultaneous procedures
and 1 staged procedure. The heart was transplanted first in all cases. All patients
were maintained after transplantation on azathioprine (2 mg · kg1 · d1) and
whole-blood monoclonal cyclosporine levels at greater than 200 g/L; prednisone
was not decreased to less than 10 mg/d.
Results: Seven (87.5%) patients have survived a mean duration of 100.4 months
(range, 51-144 months), and each allograft has continued to function. The only death
was due to pulmonary emboli and was not related to allograft rejection or failure.
Only 4 cardiac and 4 kidney allograft rejections have occurred. Five patients have
been free of kidney rejection, 1 patient has been rejection free for more than 8 years,
and no patient has had simultaneous rejection.
Conclusions: In select patients, combined heart and kidney transplantation can
provide long-term graft function and patient survival. The low rates of rejection
support our current approach to immunosuppression. Our experience indicates that
end-stage failure of either heart or kidney does not necessarily preclude dual-organ
transplantation.
Heart and kidney transplantation has made great progress in thecyclosporine era. At our institution, patient 1-year survivals forheart and kidney (HTK) transplant recipients are 93% and 98.4%,respectively. Coupled with the growing successes in individualsolid organ transplantation, there has also been an increase in thenumber of multiple organ transplants, such as pancreas/kidney,
heart/lung, heart/liver, and liver/kidney.1-5 This trend has been in part due to a better
understanding of immunobiology, advances in surgical technique and postoperative
care, and an often-common pathologic association between dual-organ failure. This
pathologic course is exemplified for end-stage heart failure leading to secondary
renal dysfunction or failure, or for end-stage renal failure as a cause for (uremic)
cardiomyopathy. However, refractory cardiac failure has long been considered a
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contraindication to kidney transplantation. Additionally,
cardiac transplantation has been denied for patients with
end-stage renal disease. Over recent years, combined HTK
transplantation has been offered to select patients who were
once denied transplantation.
There have been several case reports and small series
documenting the feasibility of performing either simulta-
neous or staged HTK transplantation.6-15 However, long-
term data regarding immunosuppression protocols, rejection
profiles, and graft and patient outcomes have not been
detailed. We report a single-institutional experience with
combined HTK transplantation with follow-up extending
beyond 10 years.
Patients and Methods
From January 1990 to March 1998, 8 patients with a mean age of
45.9 years (range, 29-59 years) underwent combined HTK trans-
plantation. Each patient met standard criteria for orthotopic heart
transplantation initially and was then deemed an acceptable can-
didate for kidney transplantation. Primary heart or kidney disease
as an etiology for dual-organ failure was not an exclusion criterion,
but difficult-to-manage diabetes, diabetic retinopathy or neuropa-
thy, extensive peripheral vascular disease, or age older than 60
years were reasons for exclusion. The etiology of end-stage heart
failure was idiopathic cardiomyopathy (n  5), ischemic cardio-
myopathy (n  2), and alcohol cardiomyopathy (n  1). Each
patient had severe fixed impairment of systolic cardiac function
with an average ejection fraction of 17.8% (range, 10%-23%) and
New York Heart Association class III or IV symptoms. Renal
failure or dysfunction was caused secondary to primary cardiomy-
opathy (n  4), polycystic kidney disease (n  2), and autoim-
mune disorder (n  1) or secondary to multisystem organ failure
after cardiac transplantation (n  1). Six of these patients had
irreversible end-stage renal failure managed by dialysis. In 1 of
these patients, hemodialysis-dependent renal failure developed
after insertion of a left ventricular assist device for decompensat-
ing heart failure. Two other patients had severe renal dysfunction
with an average glomerular filtration rate (GFR) of 34 mL/min and
an average creatinine level of 2.6 mL/dL on maximal medical
therapy for heart failure. The patient profiles are summarized in
Table 1.
Donors were matched for each recipient on the basis of donor
and recipient weight, recipient transpulmonary gradient, and ABO
blood group identity. The immunologic profiles are listed in Table
2. Selection was not based on prospective HLA antigen matching
except for the 1 staged procedure, for which the 2 most recent
candidates had documented panel-reactive antibodies20%. Rou-
tine retrospective lymphocytotoxic cross-matching was performed
and available hours after implantation.
The donor organs were procured and implanted by members
from the Emory University transplant team. At the time of pro-
curement, each heart was perfused and stored at 4°C in 1 L of Roe
cardioplegic solution. The kidneys were perfused en bloc with
other abdominal organs with University of Wisconsin solution and
stored at 4°C in 1 L of University of Wisconsin solution. The heart
was implanted first in all cases. After the patient was weaned from
cardiopulmonary bypass and hemodynamic stability was attained,
heparin was reversed and hemostasis was achieved, and then the
chest was closed and drained. Kidney implantation was then per-
formed without delay in standard fashion. All patients were man-
aged jointly in the cardiovascular surgical intensive care unit,
although each patient remained under the direct care of the heart
transplant team until discharge.
Preoperative immunosuppression consisted of cyclosporine 2
to 3 mg/kg, azathioprine 3 to 4 mg/kg, and methylprednisolone
(Solu-Medrol) 500 mg intravenously (IV). Thereafter, immuno-
suppression was maintained with whole-blood cyclosporine (INN:
ciclosporin) levels of more than 200 g/L, azathioprine 2 mg ·
kg1 · d1, and methylprednisolone 125 mg IV every 8 hours for
6 doses. Prednisone was then started at 1 mg · kg1 · d1 in
divided doses; it was weaned by 5 mg/d to 20 mg/d and then to a
maintenance dose of 10 mg/d over the subsequent 6 to 12 months.
Rejection was monitored in the case of hearts by surveillance
endomyocardial biopsies (EMB) commencing on day 7, then
weekly for 4 weeks, twice monthly for 3 months, monthly until 6
months, and then every 2 months until 1 year. Patients underwent
EMB every 3 months until year 2, and then they had an EMB once
or twice yearly or in cases of suspected graft rejection. For the
kidneys, rejection was generally monitored by noninvasive means,
TABLE 1. Patient demographics and clinical characteristics
Patient no. Age (y) Sex Heart disease Kidney disease EF (%) Dialysis LVAD
1 44 M ICM PCD 23 Yes No
2 49 M ICM HTN 14 No No
3 48 M AL CM ATN* 30 No Yes
4 36 M IDCM ATN* 15 Yes No
5 29 M IDCM HTN 18 Yes No
6† 59 M IDCM ATN* 17 Yes No
7 53 M IDCM PCD‡ 15 Yes No
8 44 F IDCM Auto HTN 10 Yes No
ATN, Acute tubular necrosis; AL CM, alcohol cardiomyopathy; Auto, autoimmune; EF, ejection fraction; F, female; HTN, hypertension; ICM, ischemic
cardiomyopathy; IDCM, idiopathic cardiomyopathy; LVAD, left ventricular assist device; M, male; PCD, polycystic kidney disease.
*ATN was caused by consequences of end-stage heart failure.
†This patient had a staged kidney transplantation 2 years after complications from a previous heart transplantation.
‡PCD was the primary disease, but the patient required a second kidney transplantation after allograft failure 7 years earlier.
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including serum creatinine levels, but it was always documented
by graft kidney biopsy. Allograft kidney biopsy or cardiac biopsy
was not performed empirically in cases of isolated single allograft
rejection.
Infection prophylaxis against Pneumocystis carinii pneumonia
consisted of a daily co-trimoxazole (Bactrim DS ) tablet. In gen-
eral, no prophylaxis was given for cytomegalovirus unless a pos-
itive seroconversion, infection, or disease was documented from
shell-vial or polymerase chain reaction analysis. Therapy consisted
of IV ganciclovir therapy (5 mg/kg every 12 hours); the duration
of treatment varied throughout the study period. Follow-up care
was maintained in cooperation between the HTK transplant teams.
Survival was determined by the Kaplan-Meier method.
Results
The rejection profiles, clinical results, and outcomes are
summarized in Table 3. There was 7 simultaneous HTK
transplantations and 1 staged HTK transplantation. The
donor was the same in 6 of 7 simultaneous transplantations;
the other was a living related kidney donor. The mean
ischemic time for the cardiac allografts (n  8) was 93.8 
42 minutes, and for the kidney allografts (n  7) it was
470.7  271 minutes. There were no intraoperative or
perioperative complications.
There was only 1 cardiac allograft rejection episode
(International Society of Heart and Lung Transplantation
[ISHLT] grade 2) in each of 4 patients, and there were 2
kidney allograft rejection episodes in each of 2 patients. The
range for the time to first cardiac rejection was 5 to 34
months, and for kidney rejection it was 1 and 37 months. All
rejection episodes responded to standard therapy. Moreover,
there has not been a documented cardiac allograft rejection
since April 1995 or a kidney allograft rejection since Jan-
uary 1995. Five patients are free of kidney rejection, 1 patient
has been rejection free for more than 6 years, and no patient
has had simultaneous HTK rejection. Therefore, there have
been a total of 8 rejection episodes in a total cumulative
follow-up period of 694 graft-months in surviving patients.
Cardiac complications in follow-up have been bradycar-
dia requiring a DDD pacemaker (n  2), hypertension
requiring augmentation of therapy (n  2), and cardiac
allograft dysfunction unrelated to coronary vasculopathy
(leading to subsequent staged kidney transplantation; n 
1). Renal allograft complications have been renal insuffi-
ciency secondary to hypertension, cyclosporine, or both (n
 1) and urinary traction infection (n  1). All kidney
allografts are functioning; the mean GFR in the surviving
patients is 65  15 mL/min. There has been no significant
coronary vasculopathy in any patient, but 1 patient had a
50% diameter left anterior descending artery occlusion. The
cardiac function has remained normal in 6 of 7 surviving
patients, the mean ejection fraction for these patients has
been 56%  13%, and all patients are New York Heart
Association class I or II. Early or late infections with
cytomegalovirus have not been a concern.
Seven (87.5%) of 8 patients have survived a mean of
100.4  38.7 months (range, 51-144 months) with 100%
graft survival. The patients’ cumulative survival at 30 days
and 1 year was 100% and 87.5%, respectively (Figure 1).
Five patients thus far have lived beyond 5 years, and the
patient who has survived longest has lived beyond 12 years.
The 1 patient death occurred 31 days after simultaneous
transplantation because of pulmonary emboli and was not
related to allograft rejection or failure.
TABLE 2. Immunologic profile
Patient
no.
PRA
(%) Cross-match
HLA HLA mismatch
(AB/DR)
Ischemic time (min)
Recipient Donor Heart Kidney
1 0 Negative A: 24, 29; B: 27, 44;
DR: 4, 7
A: 1, 2; B: 8, 57;
DR: 3, 7
4/1 121 556
2 0 Negative A: 26, 28; B: 14, 53;
DR: 7, 8
A: 2, 33; B: 14, 60;
DR: 12
3/2 58 306
3 0 Negative A: 2, 25; B: 7, 44;
DR: 4, 13
A: 2, 28; B: 44, 60;
DR: 11, 15
2/2 32 Living
related
4 N/A Negative A: 2, 28; B: 60, XX;
DR: 8, XX*
A: 3, 11; B: 44;
DR: 1, 11
4/2 54 244
5 0 Negative A: 2, 28; B: 58, XX;
DR: 12, XX
A: 1, 24; B: 38, 60;
DR: 1, 7
4/2 75 296
6 0 Negative A: 3, 30; B: 7, 35;
DR: 1, 11
A: 3, XX; B: 7, 35;
DR: 7, 15
1/2 123 1093
7 44/0 Negative† N/A N/A N/A 159 560
8 20 Negative† N/A N/A N/A 128 380
PRA, Panel-reactive antibody; N/A, not applicable.
*XX represents unidentified HLA typing and was regarded as a mismatch.
†These patients were prospectively HLA typed because of increased PRA. Even though patient 7 was able to have the PRA reduced with dithiothreitol,
there was a history of kidney allograft loss.
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Discussion
The documentation of successful combined HTK transplan-
tation continues to grow.6-15 In a corroborative report using
data from the ISHLT and United Network for Organ Shar-
ing, there were 84 simultaneous HTK transplantations per-
formed between 1987 and 1995, with a mean follow-up of
2 years.3 A wider application of HTK transplantation in the
current arena of scarce donor resources may not be fully
realized until long-term outcome data are available docu-
menting patient and graft survival comparable to those with
single-organ transplantation. Although clinical experience
with heart transplantation has allowed expansion of selec-
tion criteria, patients with end-stage heart disease and
chronic renal dysfunction are generally excluded from sin-
gle cardiac transplantation. Additionally, patients with end-
stage renal failure with concomitant severe cardiac dysfunc-
tion are refused kidney transplantation. As the waiting lists
for heart or kidney transplantation continue to increase, the
potential for second-organ dysfunction that requires consid-
eration for multiorgan transplantation may occur in larger
proportions. The kidney remains the most vulnerable ex-
trathoracic organ in patients awaiting heart transplantation.
Patients with either organic kidney disease (eg, polycystic
kidney disease) or intrinsic renal disease as a consequence
of systemic conditions (eg, hypertension or diabetes) have
the added burden of a low cardiac output, which can lead to
or potentiate renal dysfunction.16 The rationale for inclusion
of patients for simultaneous transplantation who have both
cardiomyopathy and dialysis-dependent renal failure or
pathologic kidney disease (eg, polycystic kidney disease) is
more evident than in those patients who have a primary
cardiomyopathy and secondary renal insufficiency or dys-
function. In the ISHLT registry, approximately 20% of
patients selected by criteria for heart transplantation alone
had some component of renal insufficiency at 1 year.3
Moreover, in one report, 55.3% of patients with pre–heart
transplantation creatinine greater than 1.5 mg/dL had
chronic renal insufficiency, and for this subgroup, 28.5%
became dialysis dependent.16 The cause of renal insuffi-
ciency has been attributed to the adverse effects of cyclo-
sporine and glucocorticoids,17-19 because hypertension, hy-
perlipidemia, and diabetes occurred in 18% to 67% of these
same patients by 1 year.3 Cases of dialysis-dependent renal
failure due to long-term cyclosporine toxicity can also oc-
TABLE 3. Rejection profile and outcome data
Patient
no.
Rejection
Adverse event
EF
(%)
GFR > 50
(mL/min) Survival
Follow-up
(mo)Heart Kidney
1 1 2 HTN 60 Yes Alive 144
2 1 0 Pacemaker 60 Yes Alive 138
3 0 0 None 65 Yes Alive 97
4 0 0 PE N/A Yes Death 1
5 1 2 HTN, renal
insufficiency
55 No Alive 90
6 1 0 Pacemaker 25 Yes Alive 130
7 0 0 UTI 65 Yes Alive 51
8 0 0 None 60 Yes Alive 53
GFR, Glomerular filtration rate; HTN, hypertension; PE, pulmonary emboli; UTI, urinary tract infection; EF, ejection fraction; N/A, not applicable.
Figure 1. Actuarial survival for simultaneous heart/kidney transplantation.
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cur, although this is an extremely unusual event in our
experience and according to the ISHLT registry.3 If this has
occurred, it has usually been associated with a complicated
event, as in one of our cases. Therefore, it is our opinion that
optimally managed patients with end-stage heart failure
who have a serum creatinine greater than 1.8 mg/dL and a
GFR less than 40 mL/min are at high risk of becoming
dialysis dependent after heart transplantation and are poten-
tially more suitable candidates for an HTK transplantation,
as were 2 of the patients in this study.
In our series, except for the 1 staged procedure, no
attempt was made to perform prospective HLA matching.
Although HLA matching has been shown to be advanta-
geous not only for renal, but also for cardiac, allograft
survival,20,21 this type of prospective testing has not been
feasible in efforts to minimize cardiac ischemia. However,
the very short cold ischemia time of the kidney in the
simultaneous procedure is a significant technical advantage
of the double procedure when compared with single cadav-
eric kidney grafting, in which long cold storage is associated
with poor early function and reduced long-term graft sur-
vival.22 Whether limiting the ischemic time provides an
immunologic advantage is unclear. However, with the se-
lection of donor and recipient matching based on ABO
typing and low panel-reactive antibody results and with the
relatively short donor ischemic times, the early and long-
term rejection profiles of the simultaneous HTK recipients
in our report have been excellent. We also believe that
surveillance EMB, pathologic documentation of heart or
kidney rejection, careful follow-up, and, in particular, the
immunosuppressive regimen have been important elements
in our management strategy. In contrast to our heart trans-
plantation population, which undergoes routine weaning of
immunosuppressive therapy, whole-blood cyclosporine lev-
els are maintained at greater than 200 g/L, and prednisone
is not weaned after 6 months but is kept at 10 mg/d in the
HTK recipients. This philosophy is different from that with
isolated heart or kidney transplantation, in which pred-
nisone is attempted to be completely weaned after the initial
6 months after transplantation if there has not been a rejec-
tion episode. Also, since 1998, for isolated heart or kidney
transplantation, we have used mycophenolate mofetil in
place of azathioprine in our 3-drug regimen, which has
allowed for more patients to be weaned from steroids. For
future HTK transplantations, we will use mycophenolate
mofetil in place of azathioprine and may consider weaning
patients off steroids if the rejection profiles remain low.
Nonetheless, from our heart transplantation experience, we
do have some reservations regarding steroid weaning. We
have found that even as long as 7 years after heart trans-
plantation, 7.4% of patients will sustain a grade 2 or higher
rejection, and even at a mean follow-up at 4 years, only 50%
of heart transplant recipients will be free from acute rejec-
tion. Whether the advent of newer typing techniques using
DNA methodology for HLA class I or II typing within 2 to
4 hours on lymphocytes obtained antemortem from the
donor to allow better HTK matching will affect this immu-
nosuppressive strategy remains to be seen.
Another interesting concept is to speculate whether re-
jection in these patients has been attenuated by an altered
immune response to dual-organ transplantation.10,12,15 For
example, it is widely recognized that simultaneous pancreas
and kidney transplantation results in higher pancreas sur-
vival than if the pancreas is transplanted alone.23 Also, in
heart/lung transplant recipients, cardiac rejection is far less
common than pulmonary rejection.2,24,25 Additionally, in
combined heart/lung transplant recipients, pulmonary grafts
tend to respond more rapidly to antirejection therapy than
isolated cardiac grafts.25 These observations likely occur
because, in the simultaneous setting of organ or tissue
transplantation, the recipient immune cells do not produce
cytokines critical for clonal activation, expansion, and am-
plification of alloresponses, a term named the combi ef-
fect.26 In contrast, for our heart transplant patients, approx-
imately 30% will have a grade 2 or higher rejection within
the first year, and although this percentage decreases with
time, the risk is still present at 7 years. Also, our graft
survivals for isolated cardiac grafts at 1, 5, and 10 years
were 91%, 74.3%, and 52.3%, respectively, and for kidney
grafts at 1, 5, and 10 years they were 95%, 73%, and 44%,
respectively. In our 7 surviving HTK transplant recipients,
graft survival is 100% at a mean follow-up of 9 years. With
this report, although rejection for HTK transplantation oc-
curs within the first year, it is infrequent and not refractory,
and after 1 year it is virtually absent; this implicates the role
of dual-organ transplantation as a mechanism for immune
tolerance. The role that multiorgan transplantation may play
in extending graft acceptance and patient survival and how
it may alter or enhance our approaches to chemical immu-
nosuppression remain to be defined by future clinical inves-
tigation and research.
The complications from long-term immunosuppression
are well documented3,17,18,27 but fortunately have not been
a significant treatment issue with our patients. Hypertension
is commonplace in cyclosporine-managed renal allografts
and develops after heart transplantation as well.3,27 Because
cyclosporine-induced hypertension can yield fixed systemic
vascular disease,17,27 we liberally manage patients with a
calcium channel blocker, most recently with amlodipine at
5 to 7.5 mg/d. The potential advantages of using a calcium
channel blocker with HTK transplants are that calcium
channel blockers have the following effects on HTK allo-
grafts: (1) They improve early renal allograft function; (2)
they preserve long-term renal function in cardiac allograft
recipients; (3) they provide potential long-term protection
from coronary vasculopathy in cardiac allografts; (4) they
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allow for lower doses of cyclosporine based on the stimu-
latory effects on the P450 system; and (5) they improve
antihypertensive effects.28,29 Only 2 of 5 patients have
developed hypertension long-term that has required in-
creased doses of amlodipine or the use of adjunctive agents.
Also, all patients are maintained on statin therapy, and
pravastatin (Pravachol) (10-20 mg/d) is the cholesterol-
lowering agent of choice because of its favorable drug
interactions and pharmacokinetics with immunosuppressive
agents. To this end, diabetes, peripheral vascular disease,
hyperlipidemia, or significant coronary vasculopathy have
not occurred in the surviving patients.
One potential limiting factor to a wider application of
simultaneous HTK transplantation is the lower yield of
usable hearts to kidneys from a single donor, thereby in-
creasing the waiting time for these chronically ill patients. It
is feasible to manage patients for longer periods on the
waiting list for HTK transplantation with chronic hemodi-
alysis until a suitable donor becomes available. We cur-
rently have patients on our waiting list who fall into this
category. One alternative for this subgroup of patients, as
illustrated by one of the patients in this report, is to use a
cadaveric heart donor and a living related kidney donor.
Additionally, in the future, with wider application of me-
chanical assist devices, there may be the development of
renal failure on left ventricular assist device support,30 as in
one of our patients, and this necessitates HTK transplanta-
tion. Thus, as the number of patients with end-organ failure,
especially coexisting cardiac and kidney failure, increases,
our consideration to treat these patients by dual-organ trans-
plantation must broaden and be flexible.
In this report, we have confirmed the safety, efficacy, and
long-term success of HTK transplantation in a small number
of patients with failure of both organs. The HTK transplan-
tation procedure, however, is lengthy and potentially in-
creases the technical risks of surgery. Transplant programs
that wish to expand to multiorgan transplantation should
have an established track record in isolated cardiac and
abdominal transplantation, preferably performing more than
20 isolated transplantations per year, and have a multidis-
ciplinary team for these particular patients. Also, critical to
the success of the procedure and to the long-term manage-
ment is cooperation between the 2 transplant disciplines.
Our current approach to patient selection, treatment, and
immunosuppression is supported by low rates of rejection
and long-term graft and patient survival. Our experience
suggests that end-stage failure of either the heart or kidney
does not necessarily preclude patients from dual-organ
transplantation.
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